PUBLISHED: November 16, 2020 at 12:00 am CANTON, CT >> Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its third quarter ended September 30, 2020. “In the third quarter Kelyniam was able to capture pent-up demand and some additional market share leading to significantly increased sales compared to the same...Read More

CANTON, CT: Kelyniam Global (OTC:KLYG), a maker of custom cranial implants, today announced results for its half year ended June 30, 2020. “Despite the Covid 19’s pandemic effects, Kelyniam was able to continue operating profitably and significantly increased sales compared to the same period in 2019,” said Ross Bjella, Kelyniam’s CEO. Financial performance for the...Read More

CANTON, CT >> Kelyniam Global (KLYG), a maker of custom cranial implants, releases financial performance for the first quarter of 2020. Click here to access the report. Read More

Click here to view the 2019 financial statements.Read More

CANTON, CT >> Kelyniam Global (KLYG), a maker of custom cranial implants, released today financial performance for the third quarter of 2019. Revenue rose to $491,745 in Q3, up 27% over the previous quarter and 15% over the same quarter last year. Year to date sales are down 7% over the same period in 2018,...Read More

Dear Kelyniam Shareholders, After a record sales year in 2018, revenue from sales of our PEEK implants slowed somewhat in the first half of the year, decreasing 17% to $931,894 from $1,118,512 over the same period in the previous year. Unit volume was down 15% due to lost volume from one of our top distributors....Read More

CANTON, CT >> Kelyniam Global (KLYG), a maker of custom cranial implants announced today that it has entered into a distribution agreement with Bioplate, Inc., a leading manufacturer of cranial fixation devices for neurosurgery. Dr. Mark Smith, Kelyniam’s Vice President of Business Development said, “Bioplate’s line of plates and screws for cranial and craniofacial surgeons...Read More

Click Here to view the Financial Statment for the period ending March 31, 2019  Read More

CANTON, CT >> Kelyniam Global (KLYG), a maker of custom cranial and craniofacial implants, announced today that it has received premarket approval from the Food and Drug Administration (FDA) for a new 510(k) application that allows for unique modifications to their PEEK cranio-maxillofacial implant product line. This approval means Kelyniam can now sell the only...Read More

To the Shareholders of Kelyniam Global, Inc. Kelyniam achieved record sales in 2018 by growing 15% to $2,123,699, marking two years in a row of double digit growth. Unit sales increased 11% and the average selling price per unit increased nearly 5% over 2017. Despite this success, we were expecting more. Our program to produce...Read More